4-Hydroxycordoin | 55524-25-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 4-Hydroxycordoin
• 英文别名: p-hydroxycordoin；(2E)-1-{2-hydroxy-4-[(3-methylbut-2-enyl)oxy]phenyl}-3-(4-hydroxyphenyl)prop-2-en-1-one；(E)-1-[2-hydroxy-4-(3-methylbut-2-enoxy)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one
• CAS: 55524-25-9
• 化学式: C₂₀H₂₀O₄
• 分子量: 324.376
• InChiKey: SFXYAAFUXNWNQF-BJMVGYQFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-[2-羟基-4-(3-甲基-2-丁烯氧基)-苯基]-乙酮 、 对羟基苯甲醛 在 potassium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 以32%的产率得到4-Hydroxycordoin
  参考文献：
  名称：

  Prenyloxyphenylpropanoids as a novel class of anticonvulsive agents

  摘要：

  In this study, we synthesized some natural and semi-synthetic prenyloxyphenylpropanoids (e.g., acetophenones, benzoic and cinnamic acids, chalcones, and coumarins), and we assessed their in vivo neuroprotective activity, using the mouse maximal electroshock-induced seizure model (MES test). 7-Iso-pentenyloxycoumarin and (2E)-3-{4-[(3-methylbut-2-enyl)oxy]phenyl}prop-2-enoic acid, administered ip at a dose of 300 mg/kg, suppressed MES-induced seizures in mice in a time- and dose-dependent manner. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.110

文献信息

• [EN] SKIN PIGMENTATION MODIFIERS TO DARKEN OR LIGHTEN THE SKIN<br/>[FR] AGENTS DE MODIFICATION DE LA PIGMENTATION DE LA PEAU EN VUE DE L'ASSOMBRIR OU DE L'ÉCLAIRCIR
  申请人：AFFICHEM

  公开号：WO2016193220A1

  公开（公告）日：2016-12-08

  The present invention relates to a method for changing the pigmentation of a skin, a mucous membrane or hair with a compound of general formula (I), a cosmetic use of said compound of general formula (I), to cosmetic compositions comprising said compound of general formula (I), and to new depigmenting agents.

  本发明涉及一种改变皮肤、粘膜或头发色素的方法，使用一般式(I)的化合物，以及所述一般式(I)的化合物的化妆用途，包括所述一般式(I)的化合物的化妆组合物，以及新的脱色剂。
• DEPIGMENTING AGENTS TO LIGHTEN THE SKIN
  申请人：Affichem

  公开号：EP3097904A1

  公开（公告）日：2016-11-30

  The present invention relates to a method for lightening a skin or a mucous membrane with a depigmenting agent, a cosmetic use of said depigmenting agent, to cosmetic compositions comprising said agent, and to new depigmenting agents.

  本发明涉及一种使用脱色剂淡化皮肤或粘膜的方法、所述脱色剂的化妆品用途、包含所述脱色剂的化妆品组合物以及新型脱色剂。
• Antibacterial and Anti-inflammatory Activities of 4-Hydroxycordoin: Potential Therapeutic Benefits
  作者：Mark Feldman、Shinichi Tanabe、Francesco Epifano、Salvatore Genovese、Massimo Curini、Daniel Grenier

  DOI：10.1021/np100547b

  日期：2011.1.28

  4-Hydroxycordoin (1), a natural isopentenyloxychalcone, is a plant secondary metabolite that is relatively rare. Since there are very few reports about the biological activities of 1, its potential benefits for periodontal disease were investigated. A marked and dose-dependent antibacterial activity of 1 was observed against the three major periodontal pathogens, Porphyromonas gingivalis, Fusobacterium nucleatum, and Prevotella intermedia. Moreover, compound 1 showed an antiadhesion effect, since it inhibited attachment of P. gingivalis to oral epithelial cells. Finally, using a macrophage model, the ability of 1 to inhibit the secretion of inflammatory mediators induced by Aggregatibacter actinomycetemcomitans lipopolysaccharide was demonstrated. The anti-inflammatory effect observed was associated with reduced activation of the nuclear factor-kappa B (NF-kappa B) p65 and activator protein-1 (AP-1) pathways.
• CHALCONES AND ESTERS THEREOF WITH ANTIPROLIFERATIVE ACTIVITY IN UTERUS, OVARY AND BREAST TUMOURS
  申请人：INDENA S.p.A.

  公开号：EP0800387A1

  公开（公告）日：1997-10-15
• MRGPRX2 ANTAGONIST FOR THE TREATMENT OF PSEUDO ALLERGIC REACTIONS
  申请人：The University of Hong Kong

  公开号：US20220401435A1

  公开（公告）日：2022-12-22

  Compounds that have antiallergic and/or anti-inflammatory properties and methods of making thereof are disclosed. These compounds can block MMRGPRX2 and prevent or reduce mast cells activation. Pharmaceutical formulations in a unit dosage form suitable for the delivery of the compounds to a subject in need thereof are disclosed. The pharmaceutical formulations may include one or more active agents in addition to the compounds, such as one or more additional antiallergic and/or anti-inflammatory agents. The pharmaceutical formulation can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. Methods for preventing or treating pseudo allergic reactions, pseudo allergic diseases, and/or pseudo inflammatory diseases, or treating or ameliorating one or more symptoms associated with a pseudo allergic reaction, a pseudo allergic disease, and/or a pseudo inflammatory disease in a subject are also disclosed.